Who
Eli Samaha
Director
Company insider
Files Form 4 as: Director, Stagwell; 10% owner, Theravance Biopharma; 10% owner, Synovus Financial; 10% owner, Pfsweb.
In numbers
- Trades disclosed
- 79
- Buys
- 39
- Sells
- 14
- Bought
- $64.1M
- Sold
- $37.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 9 Aug 2021
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K2,457 at $8.14 | filing |
| 7 Jul 2026filed 8 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $96K5,564 at $17.17 | filing |
| 7 Jul 2026filed 8 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $96K5,564 at $17.17 | filing |
| 6 Jul 2026filed 8 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $24K1,400 at $17.04 | filing |
| 6 Jul 2026filed 8 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $24K1,400 at $17.04 | filing |
| 1 Jul 2026filed 2 Jul 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K2,691 at $7.43 | filing |
| 1 Jul 2026filed 2 Jul 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K2,691 at $7.43 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $643K37,799 at $17.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $643K37,799 at $17.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $429K25,027 at $17.13 | filing |
| 30 Jun 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $429K25,027 at $17.13 | filing |
| 29 Jun 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $4.7M273,871 at $17.23 | filing |
| 29 Jun 2026filed 1 Jul 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Sold | $4.7M273,871 at $17.23 | filing |
| 11 Jun 2026filed 12 Jun 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | —22,970 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | —22,970 at $0.00 | filing |
| 1 Apr 2026filed 2 Apr 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K3,180 at $6.29 | filing |
| 1 Apr 2026filed 2 Apr 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K3,180 at $6.29 | filing |
| 2 Jan 2026filed 5 Jan 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K4,090 at $4.89 | filing |
| 2 Jan 2026filed 5 Jan 2026 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K4,090 at $4.89 | filing |
| 1 Oct 2025filed 2 Oct 2025 | STGW StagwellAdvertising & Marketing | SEC FORM 4 Code A | $20K3,552 at $5.63 | filing |
News
No headline names them, or the companies they trade most, lately.